NMN vs NR vs Niacinamide: Which Actually Raises NAD+

The Short Version: What the Trial Found

Here is the result in plain terms, drawn from the January 2026 report:

That is the entire headline. What it does not say is just as important: it does not say either compound made anyone healthier, lived longer, or reversed anything. It measured a blood biomarker over two weeks. We will come back to that distinction repeatedly, because it is where most longevity coverage goes wrong.

What NMN, NR, and Niacinamide Actually Are

All three compounds are precursors in the NAD+ salvage pathway, the route your cells use to recycle and replenish nicotinamide adenine dinucleotide, a coenzyme involved in energy metabolism and cellular repair. NAD+ levels decline with age in many tissues, which is the entire premise behind supplementing precursors. The three differ by where they enter the pathway.

Nicotinamide (niacinamide) is the simplest and cheapest. It is a form of vitamin B3 and sits well-established as a nutrient. It feeds the salvage pathway directly, but as the new trial showed, oral dosing produced only an acute bump in blood NAD+ rather than a sustained rise over the two-week window.

Nicotinamide riboside (NR) is a riboside form that has been the subject of multiple human studies and is sold widely as a supplement. In this trial it roughly doubled circulating NAD+.

NMN (nicotinamide mononucleotide) is one phosphorylation step closer to NAD+ than NR in the classic diagram, which is the basis for years of marketing claims that it is superior. In this head-to-head, it roughly doubled NAD+ and performed comparably to NR. The theoretical advantage did not translate into a measurable blood-NAD+ edge here.

|---|---|---|---|

A compliance point worth stating plainly: none of these compounds is FDA-approved to treat aging or any disease. NMN in particular has had a contested regulatory history in the United States as a dietary ingredient. These are supplements, and supplement status is not the same as a demonstrated clinical benefit.

The Gut-Bacteria Wrinkle Nobody Expected

The most scientifically interesting finding is also the most humbling. The data suggested that gut bacteria convert NMN and NR to nicotinic acid before the body uses them. In other words, the clean schoolbook diagram, where you swallow NMN and it marches directly up the salvage pathway intact, does not fully describe what happens in a living person.

This matters for two reasons. First, it complicates any claim that NMN is "better because it is closer to NAD+" in the pathway, because part of what you ingest is getting routed through a different intermediate by your microbiome before it ever raises NAD+. Second, it is a reminder that human metabolism rarely respects the tidy arrows on a supplement-company infographic. The practical upshot for someone following this space is humility: the biomarker moved, but the mechanism behind that movement is more tangled than the marketing suggests.

Why "It Raised NAD+" Is Not the Same as "It Works"

This is the section that matters most, and it is the one most longevity content skips. The trial measured a single biomarker, blood NAD+, over 14 days. Raising a biomarker is a necessary first step, not proof of benefit. Plenty of interventions move a number on a lab report without changing anything you would actually feel or any outcome that matters over decades.

A 2025 systematic review of 113 studies frames exactly this problem: there is a persistent gap between strong rodent NAD+ data and more modest human outcomes. In mice, raising NAD+ has been tied to a range of striking effects. In humans, the picture is consistently more muted. That gap is the central unresolved question of the entire NAD+ field, and a two-week biomarker study, however well-designed, does not close it.

So when you read that NMN "doubled NAD+," the honest translation is: over 14 days, in 65 healthy adults, this supplement roughly doubled one blood marker. It did not measure whether participants aged more slowly, felt more energetic, or lived longer, because a 14-day study structurally cannot measure those things. Anyone selling you the leap from "doubled a biomarker" to "slows aging" is selling you the gap the systematic review just flagged.

How People Track NAD+ Precursors With Their Providers

If you are following NAD+ science, the most useful thing you can do is keep a clean, longitudinal record rather than chasing each new headline. Blood NAD+ itself is not a routine clinical test and is mostly a research measure, so most people instead track the general metabolic and safety markers that give context to any supplement or protocol they are discussing with a provider. This is about organizing your own data to bring to a clinical conversation, not self-diagnosing.

Compounds that touch energy metabolism are often discussed alongside other metabolic interventions. If you are also curious about the broader category of metabolism-linked peptides, [MOTS-c](/peptides/mots-c) is a mitochondrial-derived peptide that comes up in the same conversations, and [epithalon](/peptides/epithalon) appears frequently in longevity-peptide discussion. Neither is FDA-approved for anti-aging use, and both belong firmly in the "talk to your provider, track your data" bucket rather than the "proven" one.

[Track your supplements, protocols, and lab trends over time in one place with MyProtocolStack.](/auth/login?mode=signup)

What to Track: Biomarkers Worth Monitoring

Because blood NAD+ is mostly a research measure, people following this space typically keep an eye on the general metabolic and safety markers that put any supplement in context. None of this is a recommendation to test or treat. It is a list of what is commonly tracked so you can organize your own results and discuss them with your provider. A single value is a snapshot; a trend line over months is what makes the data genuinely useful in a clinical conversation.

You can browse the full [biomarker library](/biomarkers) for plain-language explanations of each test, and explore the broader [peptide library](/peptides) if you want structured overviews of individual compounds rather than supplement-marketing copy. The point of tracking is to visualize a trend and compare it over time, not to chase a single lab value.

How This Fits the Broader 2026 Longevity Picture

The NMN-versus-NR question has been one of the most marketed debates in the supplement world, and this trial is a useful reset. The honest takeaway is narrow but real: at 1,000 mg per day for 14 days, NMN and NR each roughly doubled blood NAD+ and looked comparable, plain nicotinamide did not sustain the same rise, and the microbiome quietly complicates the mechanism. Everything beyond that, every claim about wrinkles, energy, or years added, lives in the gap between rodent data and human outcomes that the 2025 systematic review of 113 studies put front and center.

For someone tracking their health seriously, the practical move is the same regardless of which precursor any individual study favors: keep your records clean and provider-ready, treat biomarker movement as a starting question rather than a finished answer, and let a qualified clinician interpret what any of it means for you. The science here is genuinely interesting and genuinely early. Both things can be true at once.

Frequently Asked Questions

Between NMN, NR, and plain nicotinamide, which actually raises blood NAD+?

In a randomized human trial reported in January 2026 in Nature Metabolism, NMN and NR each roughly doubled circulating NAD+ levels in 65 healthy adults over 14 days at 1,000 mg per day, and the two performed comparably to one another. Plain nicotinamide, dosed lower, raised NAD+ only acutely rather than producing the same sustained increase. The trial measured a blood biomarker over two weeks, not any health or longevity outcome.

Is NMN or NR better for raising NAD+?

In this head-to-head trial, NMN and NR performed comparably on blood NAD+, with each roughly doubling levels over 14 days. The long-standing marketing claim that NMN is superior because it sits closer to NAD+ in the salvage pathway did not translate into a measurable blood-NAD+ advantage here. The data also suggested gut bacteria convert both to nicotinic acid en route, which complicates the simple precursor-to-NAD+ picture.

Does raising NAD+ mean a supplement slows aging?

No. The trial measured blood NAD+ as a biomarker, not lifespan, healthspan, or any disease outcome, and it ran for only 14 days in 65 people. A 2025 systematic review of 113 studies highlights a persistent gap between strong rodent NAD+ data and more modest human outcomes. Raising a biomarker is a necessary first step, not proof of benefit, and no NAD+ precursor is FDA-approved to treat aging.

Are NMN and NR FDA-approved?

No. NMN and NR are sold as dietary supplements, not FDA-approved drugs, and neither is approved to treat aging or any disease. NMN in particular has had a contested regulatory history in the United States as a dietary ingredient. Supplement status is not the same as a demonstrated clinical benefit, and any decision about using them should be made with your provider.

What should I track if I am following NAD+ science?

Blood NAD+ itself is mostly a research measure rather than a routine clinical test, so people typically track general metabolic and safety markers such as fasting glucose, HbA1c, hs-CRP, and vitamin B12, and review the trends with a provider. MyProtocolStack does not provide medical advice and cannot tell you what to take. What you can do is keep an organized, longitudinal record of your protocol and relevant lab markers so your provider conversation is grounded in good data.

Sources

1. NMN.com, "Scientists Unveil Results From Human Trial Directly Comparing Three NAD+ Precursors." https://www.nmn.com/news/scientists-unveil-results-from-human-trial-directly-comparing-three-nad-precursors

2. ScienceDirect, 2025 systematic review of NAD+ precursor studies. https://www.sciencedirect.com/science/article/pii/S1568163726000498

*MyProtocolStack is a tracking and education tool, not medical advice, diagnosis, or treatment, and you should always consult a qualified healthcare professional before making any changes to your health protocol.*